Behçet's disease: Difference between revisions
| Line 31: | Line 31: | ||
==History== | ==History== | ||
Behçet disease is named after [[Hulusi Behçet]] (1889-1948), the Turkish [[dermatologist]] and scientist who first recognized the syndrome in one of his patients in 1924 and reported his research on the disease in ''Journal of Skin and Venereal Diseases'' in 1936.<ref>{{WhoNamedIt|synd|1863}}</ref> The name (''Morbus Behçet'') was formally adopted at the International Congress of Dermatology in Geneva in September 1947. | Behçet's disease is named after [[Hulusi Behçet]] (1889-1948), the Turkish [[dermatologist]] and scientist who first recognized the syndrome in one of his patients in 1924, and reported his research on the disease in ''Journal of Skin and Venereal Diseases'' in 1936.<ref>{{WhoNamedIt|synd|1863}}</ref> The name (''Morbus Behçet'') was formally adopted at the International Congress of Dermatology in Geneva in September 1947. | ||
A group of similar symptoms were | A group of similar symptoms were first described by [[Hippocrates]] in 5th century BC as part of his 3rd Epidemion book.<ref>Johns Hopkins Vasculitis Center (2004). [http://vasculitis.med.jhu.edu/typesof/behcets.html Johns Hopkins Vasculitis Center Discusses Behçets Disease]. Retrieved September 9, 2005.</ref> | ||
==Pathology== | ==Pathology== | ||
Revision as of 14:19, 11 May 2012
For patient information click here
| Behçet disease | |
| ICD-10 | M35.2 |
|---|---|
| ICD-9 | 279.4 |
| OMIM | 109650 |
| DiseasesDB | 1285 |
| eMedicine | med/218 ped/219 derm/49 oph/425 |
| MeSH | D001528 |
|
WikiDoc Resources for Behçet's disease |
|
Articles |
|---|
|
Most recent articles on Behçet's disease Most cited articles on Behçet's disease |
|
Media |
|
Powerpoint slides on Behçet's disease |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Behçet's disease at Clinical Trials.gov Trial results on Behçet's disease Clinical Trials on Behçet's disease at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Behçet's disease NICE Guidance on Behçet's disease
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Behçet's disease Discussion groups on Behçet's disease Patient Handouts on Behçet's disease Directions to Hospitals Treating Behçet's disease Risk calculators and risk factors for Behçet's disease
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Behçet's disease |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
for the heart in Behçet's disease click here
Overview
Behçet's disease (Behçet's syndrome, Morbus Behçet, silk road disease) is a chronic inflammatory condition caused by disturbances in the immune system. The immune system normally protects the body against infections through a controlled inflammatory reaction against the pathogen.In Behcet's disease, the immune response becomes overactive and produces unpredictable outbreaks of exaggerated inflammation. This extra inflammation affects blood vessels, in particular the smaller vessels. As a result, symptoms appear wherever the exaggerated inflammation response is produced, and can occur anywhere on the body where there is a blood supply.
History
Behçet's disease is named after Hulusi Behçet (1889-1948), the Turkish dermatologist and scientist who first recognized the syndrome in one of his patients in 1924, and reported his research on the disease in Journal of Skin and Venereal Diseases in 1936.[1] The name (Morbus Behçet) was formally adopted at the International Congress of Dermatology in Geneva in September 1947.
A group of similar symptoms were first described by Hippocrates in 5th century BC as part of his 3rd Epidemion book.[2]
Pathology
The symptoms of Behçet disease are believed to be caused by an over-active immune system which, without any apparent infections, produces recurrent outbreaks of inflammation in small blood vessels. Common symptoms include mouth ulcers, sore genitals and eye inflammation, and arthritis in older patients, mostly painful but not life-threatening conditions. However, some patients may be unable to work because of the pain and the impaired vision and mobility. In some severe cases, uncontrolled inflammation may lead to blindness, intestinal complications, stroke, and even meningitis, which can be fatal.
This disease usually first strikes patients in their 20s and 30s. It then becomes a fluctuating lifelong disorder with a series of remissions and exacerbations which can be from days to months. Complete remission is rare.
Diagnosis
There is no specific pathological test for Behçet disease at present. It is diagnosed clinically by specific patterns of symptoms and repeated outbreaks. Other causes for these symptoms have to be ruled out before making the diagnosis. The symptoms do not have to occur together, but can have happened at any time.
There are three levels of certainty for diagnosis:
- International Study Group diagnostic guidelines (very strict for research purposes)
- Practical clinical diagnosis (generally agreed pattern but not as strict)
- 'Suspected' or 'Possible' diagnosis (incomplete pattern of symptoms)
International Study Group diagnostic guidelines
Must have
- oral (aphthous) ulcers (any shape, size or number at least 3 times in any 12 months),
along with 2 out of the next 4 "hallmark" symptoms:
- genital ulcers (including anal ulcers and spots in the genital region and swollen testicles or epididymitis in men),
- skin lesions (papulo-pustules, folliculitis, erythema nodosum, acne in post-adolescents not on corticosteroids),
- eye inflammation (iritis, uveitis, retinal vasculitis, cells in the vitreous),
- pathergy reaction (papule >2 mm dia. 24-48 hrs or more after needle-prick).
Practical clinical diagnosis
Must have
- mouth ulcers,
along with 1 of the 4 hallmark symptoms above and with 2 of the symptoms below:
- arthritis/arthralgia,
- nervous system symptoms,
- stomach and/or bowel inflammation,
- deep vein thrombosis,
- superficial thrombophlebitis,
- cardio-vascular problems of inflammatory origin,
- inflammatory problems in chest and lungs,
- problems with hearing and/or balance,
- extreme exhaustion,
- changes of personality, psychoses,
- any other members of the family with a diagnosis of Behcet disease.
'Suspected' or 'Possible' diagnosis
Usually given when someone does not have mouth ulcers or has mouth ulcers but does not have 1 of the 4 hallmark symptoms but has other symptoms and signs of inflammation and other causes for these have been ruled out.
Causes
No one knows why the immune system starts to behave this way in Behcet disease. It is not because of any known infections, it is not hereditary, it does not have to do with ethnic origin, gender, life-style, or age, where someone has lived or where they have been on holiday. It is not associated with cancer, and links with tissue-types (which are under investigation) are not certain. It does not follow the usual pattern for autoimmune diseases.
Treatment
Current treatment is aimed at easing the symptoms, reducing inflammation, and controlling the immune system. Anti-TNF therapy such as infliximab has shown promise in treating the uveitis associated with the disease.[3][4] Another Anti-TNF agent, Etanercept, may be useful in patients with mainly skin and mucosal symptoms.[5]
Interferon alfa-2a may also be an effective alternative treatment, particularly for the genital and oral ulcers[6] as well as ocular lesions.[7] Azathioprine, when used in combination with interferon alfa-2b also shows promise,[8] and Colchicine can be useful for treating some genital ulcers, erythema nodosum, and arthritis in women, and arthritis in men.[9]
Thalidomide has also been used due to its immune-modifying effect.[10] Dapsone and rebamipide have been shown, in small studies, to have beneficial results for mucocutaneous lesions.[11][12]
A different orientation could be explored in Behçet Disease, especially with genetic linkage to HLA-B51 antigen, just like the prevalence of HLA-B27 in Ankylosing Spondylitis, a very similar condition. AS is not due to an 'oveactive' immune system, but it is a true autoimmune disease caused by molecular mimicry of the Osp (outer surface protein) with the Klebsiella pneumoniae germ (2 enzymes produced by this normally non-virulent pathogen), which is always present as a sub-clinical infection, typically at the ileocecal junction. The combination of antibiotics targeted to this specific germ, and dietary controls (elimination or severe restriction of all starches) could therefore potentially provide the most effective treatments, but such treatments have not yet been proven or generally approved.
Epidemiology
Behçet disease is considered more prevalent in the areas surrounding the old silk trading routes in the Middle East and in Central Asia. Thus, it is sometimes known as Silk Road Disease. However, this disease is not restricted to people from these regions.
An estimated 15,000 to 20,000 Americans have been diagnosed with this disease. In the UK, it is estimated to have about 2 cases for every 100,000 people.
Globally, males are affected more frequently than females. In the United States, more females are affected than males.
Pronunciation note
Because it contains a cedilla, "Behçet" is frequently wrongly assumed to be French in origin and pronounced with a sibilant "s" sound (as in "satsuma") or soft "ch" (as in "shoe"), with the "t" incorrectly silenced: "Beshay". Because Hulusi Behçet was Turkish, the correct pronunciation is with a hard "ch", as in "choice", and with the terminal "t" sounded: "Beh-chet".
References
- ↑ Template:WhoNamedIt
- ↑ Johns Hopkins Vasculitis Center (2004). Johns Hopkins Vasculitis Center Discusses Behçets Disease. Retrieved September 9, 2005.
- ↑ Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001). "Effect of infliximab on sight-threatening panuveitis in Behcet's disease". Lancet. 358 (9278): 295–6. PMID 11498218.
- ↑ Sfikakis PP (2002). "Behcet's disease: a new target for anti-tumor necrosis factor treatment". Ann Rheum Dis. 61 Suppl 2: ii51–3. PMID 12379622.
- ↑ Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005). "Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study". J Rheumatol. 32 (1): 98–105. PMID 15630733.
- ↑ Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E (2002). "Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study". Arch Dermatol. 138 (4): 467–71. PMID 11939808.
- ↑ Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N (2003). "Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis". Br J Ophthalmol. 87 (4): 423–31. PMID 12642304.
- ↑ Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H (2002). "Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study". Isr Med Assoc J. 4 (11 Suppl): 928–30. PMID 12455182.
- ↑ Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H (2001). "A double-blind trial of colchicine in Behcet's syndrome". Arthritis Rheum. 44 (11): 2686–92. PMID 11710724.
- ↑ Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial". Ann Intern Med. 128 (6): 443–50. PMID 9499327.
- ↑ Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y (2003). "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs R D. 4 (1): 19–28. PMID 12568631.
- ↑ Sharquie KE, Najim RA, Abu-Raghif AR (2002). "Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study". J Dermatol. 29 (5): 267–79. PMID 12081158.
External links
- Behçet's Disease Resource Guide from the National Eye Institute (NEI).
- Behcet disease - MedLink Neurology Clinical Summary
- Signs & Symptoms of Behçet's disease (with pictures)
- American Behçet's Disease Association
- Behçet's Syndrome Society (UK)
- International Society for Behçet's Disease
- Template:DermNet
Template:Diseases of the musculoskeletal system and connective tissue Template:SIB